Results
1 -
10 of
87Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study, Cancer Chemotherapy and Pharmacology Drugs in Clinical Development for Lung Cancer: Summary and Table, Pharmaceutical Medicine New targets for the treatment of follicular lymphoma, Journal of Hematology & Oncology Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines, Cancer Cell International Towards Targeted Therapy of Chronic Lymphocytic Leukemia, Advances in Chronic Lymphocytic Leukemia Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members, Cell Death Signaling in Cancer Biology and Treatment Targeting Bcl-2 Family Proteins in Childhood Leukemia, New Agents for the Treatment of Acute Lymphoblastic Leukemia Anti-apoptotic Bcl-2, Cancer Therapeutic Targets